It's official. Roche is joining the multibillion-dollar M&A game, acquiring a top player in the booming gene therapy business.
Image: Spark CEO Jeffrey Marrazzo at an Endpoints News panel during the 2019 JP Morgan conference Jeff Rumans for Endpoints News
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.Free Subscription